Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults With Type 1 Diabetes: A Randomized, Controlled Trial

• Published in: Diabetes care Vol. 43; no. 12; pp. 3024 - 3033
• Main Authors: McAuley, Sybil A., Lee, Melissa H., Paldus, Barbora, Vogrin, Sara, de Bock, Martin I., Abraham, Mary B., Bach, Leon A., Burt, Morton G., Cohen, Neale D., Colman, Peter G., Davis, Elizabeth A., Hendrieckx, Christel, Holmes-Walker, D. Jane, Kaye, Joey, Keech, Anthony C., Kumareswaran, Kavita, MacIsaac, Richard J., McCallum, Roland W., Sims, Catriona M., Speight, Jane, Stranks, Stephen N., Sundararajan, Vijaya, Trawley, Steven, Ward, Glenn M., Jenkins, Alicia J., Jones, Timothy W., O’Neal, David N., Halliday, Jennifer, Russell-Green, Sienna, Januszewski, Andrzej, Mohammed Husin, Hanafi, Clarke, Philip M., Ambler, Geoff R., Cameron, Fergus J., Fairchild, Jan M., King, Bruce R.
• Format: Journal Article
• Language: English
• Published: United States American Diabetes Association 01.12.2020
• Subjects: Adults; Blood; Blood glucose; Cognition; Diabetes; Diabetes mellitus; Diabetes mellitus (insulin dependent); Glucose; Glucose monitoring; Insulin; Monitoring; Research design; Sleep; Well being
• ISSN: 0149-5992; 1935-5548; 1935-5548
• DOI: 10.2337/dc20-1447

To investigate glycemic and psychosocial outcomes with hybrid closed-loop (HCL) versus user-determined insulin dosing with multiple daily injections (MDI) or insulin pump (i.e., standard therapy for most adults with type 1 diabetes). Adults with type 1 diabetes using MDI or insulin pump without continuous glucose monitoring (CGM) were randomized to 26 weeks of HCL (Medtronic 670G) or continuation of current therapy. The primary outcome was masked CGM time in range (TIR; 70-180 mg/dL) during the final 3 weeks. Participants were randomized to HCL ( = 61) or control ( = 59). Baseline mean (SD) age was 44.2 (11.7) years, HbA was 7.4% (0.9%) (57 [10] mmol/mol), 53% were women, and 51% used MDI. HCL TIR increased from (baseline) 55% (13%) to (26 weeks) 70% (10%) with the control group unchanged: (baseline) 55% (12%) and (26 weeks) 55% (13%) (difference 15% [95% CI 11, 19]; < 0.0001). For HCL, HbA was lower (median [95% CI] difference -0.4% [-0.6, -0.2]; -4 mmol/mol [-7, -2]; < 0.0001) and diabetes-specific positive well-being was higher (difference 1.2 [95% CI 0.4, 1.9]; < 0.0048) without a deterioration in diabetes distress, perceived sleep quality, or cognition. Seventeen (9 device-related) versus 13 serious adverse events occurred in the HCL and control groups, respectively. In adults with type 1 diabetes, 26 weeks of HCL improved TIR, HbA , and their sense of satisfaction from managing their diabetes compared with those continuing with user-determined insulin dosing and self-monitoring of blood glucose. For most people living with type 1 diabetes globally, this trial demonstrates that HCL is feasible, acceptable, and advantageous.